Skip to content

Research Rut: Beefed Up Federal AIDS Vaccine Program Found to Suffer from Lingering Shortcomings

TAGline • 2000
Beefed Up Federal AIDS Vaccine Program Found to Suffer from Lingering Shortcomings April 2000 Tethered to the Past The first two decades of AIDS vaccine research have been characterized by a series of disappointments and setbacks. Indeed, while at the epidemic’s outset many predicted that it would be easier to develop a vaccine for HIV…

Bonanza: With Demand for Treatment Breaks at Record Level, Market for Tiny, Uninterpretable Studies Flourishes

TAGline • 2000
With Demand for Treatment Breaks at Record Level, Market for Tiny, Uninterpretable Studies Flourishes April 2000 Diverse Definitions At least eighteen studies and speeches presented at the Seventh Retrovirus Conference included discussions related to treatment interruptions (TIs) and structured treatment interruptions (STIs) in various HIV infected populations — including primary HIV infection (three papers), chronic…

Being There: Durban Delegates Return Stateside, Fired Up and Ready to Jump Back Into the Fray

TAGline • 2000
Durban Delegates Return Stateside, Fired Up and Ready to Jump Back Into the Fray September 2000 A Mouse Roars “The answer does not lie with donations or price cuts from drug companies but rather with the mass production of quality generics. This could result in the cost of a year’s antiretroviral treatment being cut to…

Agouron and Immune Response to Bridge Rx Gap

TAGline • 2000
April 2000 Those smug Cassandras will be choking on regurgitated crow once they catch wind of this noticia. Southeast Asia may be on the verge of its very own licensed HIV vaccine. Haul out the champagne. According to an item appearing in the March 24, 2000 Wall Street Journal, Thai researchers plan to recommend commercial…

Taking it to the Street: Thousands Strong, Fledgling South African Activist Group Sends Tremors Around the Globe

TAGline • 2000
Thousands Strong, Fledgling South African Activist Group Sends Tremors Around the Globe September 2000 “Defiance Campaign” in the Offing Sunday afternoon as the Durban conference was just gearing up, some five thousand demonstrators singing, chanting and dancing marched from Durban City Hall to the stadium, calling on world pharmaceutical makers to cede the Third World…

Call To Arms: Africa to Asia, Caribbean to Kazakhstan, An Explosive Epidemic Said To Threaten Backbone of Civil Society

TAGline • 2000
Africa to Asia, Caribbean to Kazakhstan, An Explosive Epidemic Said To Threaten Backbone of Civil Society August 2000 A Demographic Catastrophe “I’m not someone who blames the West for everything. I do believe that the great moral test of our time is how the rich countries respond to the AIDS crisis. But AIDS has not…

Striking the Balance: Brave New World of Human Gene Sequencing Finds Porous Policy Guidelines to Its Liking

TAGline • 2000
Brave New World of Human Gene Sequencing Finds Porous Policy Guidelines to Its Liking June 2000 Generation Gape “If somebody uses this gene . . . after the patent has been issued . . . we’d be entitled not just to damages, but to double and triple damages.” — William Haseltine, Los Angeles Times, February 28, 2000 “There is no patent.…

Structured Treatment Interruptions (STIs) from the Seventh Retrovirus Conference, 2000

Publication • 2000
February 2000 New York, NY by Mark Harrington At least 18 studies and speeches presented at the Seventh Retrovirus Conference included discussions related to treatment interruptions (TIs) and structured treatment interruptions (STIs) in various HIV infected populations — including primary HIV infection (three papers), chronic and virally suppressed (13 papers), and chronic and unsuppressed (two…

Gotcha: HIV Antibody Breakthrough in Transgenic Mice Could Prove Boon to Vaccine Effort

TAGline • 1999
HIV Antibody Breakthrough in Transgenic Mice Could Prove Boon to Vaccine Effort Formaldehyde frozen fusion Recombinant HIV envelope vaccines to date have demonstrated the ability to elicit neutralizing antibodies to HIV strains from which they were constructed (as well as against selected laboratory adapted strains), but only rarely have they resulted in the production of…

Data Be Damned: AIDSVax Field Trial Makes a Splash While Humble Canarypox Phase II Plods Along Uncelebrated

TAGline • 1999
AIDSVax Field Trial Makes a Splash While Humble Canarypox Phase II Plods Along Uncelebrated AIDS ‘end game’ While precious little has changed on the HIV vaccine front since last summer, when California-based VaxGen received the go-ahead to proceed with a Phase III “field” trial of its gp120-based AIDSVax (B/B’) product in North America, the recent…
Back To Top